Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Medicell Technologies LLC is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are handled by 2 distinct examiners located in 2 distinct art units. This distribution indicates that each active case is being reviewed independently by different personnel, rather than being consolidated under a single examiner or art unit. The 2 pending office actions represent the current active workload for the company in this sector.
The busiest examiner for this portfolio is HIRT, ERIN E, who is responsible for 1 pending office action. With 2 distinct examiners for the 2 pending office actions, the prosecution strategy must account for the specific tendencies of each individual. The lack of overlap between the 2 distinct art units suggests that the underlying technologies, while both in Biotechnology & Pharmaceuticals, are specialized enough to warrant different departmental assignments at the patent office. Practitioners should prepare for 2 separate prosecution tracks, as the 2 distinct art units may apply different examination standards to the pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRT, ERIN E | 1 | 40.6% | +22.9% |
| YU, HONG | 1 | 31.1% | +5.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18754637 | STEM CELL STIMULATING COMPOSITIONS AND METHODS | HIRT, ERIN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18754637 | STEM CELL STIMULATING COMPOSITIONS AND METHODS | HIRT, ERIN E | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18754637 | STEM CELL STIMULATING COMPOSITIONS AND METHODS | HIRT, ERIN E | 1616 | §102§103Other | Final Rejection | — | Pending | Jun 26, 2024 |
| 17930842 | STEM CELL STIMULATING COMPOSITIONS AND METHODS | YU, HONG | 1614 | §103 | Non-Final OA | — | Pending | Sep 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedicell Technologies LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Erin E Hirt has the most, with 1 of Medicell Technologies LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
